Currently, there are several clinical trials for remyelination in MS patients, including trials testing the effects of vagus nerve stimulation (NCT06641271), thyroid hormone (NCT02760056), a type 2 diabetes drug metformin (NCT05893225), and an N-methyl-D-aspartate (NMDA) receptor inhibitor ifendropil (NCT06330077). This evidence concerns the gene TG and myeloid sarcoma.